Skip to main content

ImmunityBio, Inc.

IBRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001326110

In the last 90 days, ImmunityBio, Inc. insiders filed 0 open-market purchases and 2 sales; 405 institutions reported holding it in 13F filings for Q2 2026, worth $1.76B in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding ImmunityBio, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of IBRX: Q3 2022 compared with Q4 2022
MeasureQ3 2022Of which not filed for Q4 2022Q4 2022Change
Holders1262140+16
Shares39.5M23.9K50.0M+10.5M (+26.7%)
Value$196.3M$118.0K$256.0M+$59.8M (+30.5%)

2 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (27)

Institutions that held ImmunityBio, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Sold out (11)

Institutions that held ImmunityBio, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of IBRX in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
D. E. Shaw & Co., Inc.678,504$3.37M
Millennium Management LLC399,271$1.98M
Oracle Investment Management Inc315,322$1.57M
BNP Paribas Arbitrage, SA148,282$737.0K
Ensign Peak Advisors, Inc57,690$287.0K
Man Group plc22,600$112.0K
Cubist Systematic Strategies, LLC20,700$103.0K
Quantbot Technologies LP12,424$61.0K
Signaturefd, LLC3,845$19.0K
West Oak Capital, LLC1,500$7.00K
Parallel Advisors, LLC275$1.00K

Not filed for Q4 2022 yet (2)

Institutions that held ImmunityBio, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding IBRX in Q3 2022 that haven't filed for Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
CPWM, LLC23,630$117.0K
Covington Capital Management250$1.00K